From: Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells
patient | sex | age | diagnosis | Karyotype mol biol | therapy* | response§ | relapse | OS§§ |
---|---|---|---|---|---|---|---|---|
Ph- B-ALL | ||||||||
#01 | M | 22 | B common | normal | 1 + 2 | CR | Yes | 29+ |
#02 | M | 40 | Pre-B | NA | 1 + 2 | CR | No | 24+ |
#03 | M | 16 | B common | normal | 1 | CR | Yes | 12 |
#04 | M | 45 | Pre-B | normal | 1 + 2 | CR | No | 38+ |
#05 | F | 53 | B common | hyperdiploid | 1 | CR | No | 71+ |
#06 | F | 48 | Pro-B | t(4;11) | 1 | CR | Yes | 8 |
#07 | F | 42 | Pro-B | t(4;11) | 1 | CR | Yes | 6 |
#08 | M | 41 | Pre-B | t(6;8) | 1 | CR | Yes | 19 |
#09 | M | 59 | Pro-B | t(4;11) | 1 | CR | Yes | 10 |
#10 | F | 19 | B common | hyperdiploid | 1 | CR | No | 55+ |
#11 | M | 17 | B common | t(17;22) | 3 | CR | No | 9+ |
#12 | F | 53 | B common | NA | 1 | CR | Yes | 13+ |
#13 | F | 43 | B common | normal | 1 + 2 | CR | Yes | 25 |
#14 | F | 17 | B common | normal | 3 | NR | Yes | 4 |
Ph+ B-ALL | ||||||||
#01 | M | 44 | Pre-B | Ph masked p210 (Y253H) | IM + D + 2 | CR | No | 12+ |
#02 | F | 54 | B common | t(9;22) p210 | 1 (pre-IM) | no CR | 36 | |
#03 | M | 64 | Pre-B | t(9;22) p210 | IM | CHR, CCyR | Yes | 9 |
#04 | M | 19 | B common | t(9;22) NA (E255V) | 1 + IM + N | no CHR | 16 | |
#05 | M | 40 | Pre-B | t(9;22),-10 p210 | 1 + IM + D | CHR, CCyR | Yes | 15 |
#06 | F | 38 | Pre-B | t(9;22) p190 (T315I) | 1 + IM + D | no CHR | 9 | |
#07 | M | 17 | B common | t(9;22) p210 | 1 (pre-IM) + 2 | CR | Yes | 11 |
#08 | M | 70 | Pre-B | t(9;22) NA | 5 (pre-IM) | no CR | 1 | |
#09 | M | 35 | B common | t(9;22), del(6) p190 | 1 + IM + 2 | CCyR, MMR | No | 46+ |
#10 | M | 63 | B common | t(9;22) p190 | IM + CS | CCyR, MMR | No | 15+ |
#11 | F | 75 | B common | hyperdiploid, t(9;22), NA | 5 (pre-IM) | no CR | 14 | |
#12 | M | 89 | Pre-B | t(9;22) p190 | IM | CCyR, MMR | Yes | 22+ |
#13 | F | 27 | B common | t(9;22) p190 | 1 + IM | no CHR | 10 | |
#14 | M | 28 | B common | t(9;22) p190 | 1 + IM + 2 | CR | Yes | 37 |
AML | ||||||||
#01 | M | 59 | M2 | +4,+8 | 4 | PR | Yes | 7 |
#02 | M | 46 | M0 | NA | 4 | TD | 1 | |
#03 | F | 37 | M4 | del(X)(p21) | 4 | CR | No | 167+ |
#04 | F | 47 | M2 | normal | 4 | NR | Yes | 20 |
#05 | F | 70 | M4 Eo | inv(16) | 4 | NR | no CR | 6 |
#06 | M | 74 | M4 | normal | 5 | 2 | ||
#07 | M | 62 | M4 | normal | 4 | NR | no CR | 5 |
#08 | M | 69 | M4 Eo | NA | 5 | 5 | ||
#09 | M | 60 | M2 | -7 | 4 | CR | No | 38+ |
#10 | M | 83 | M2 | NA | 5 | 3 | ||
#11 | M | 88 | M2 | NA | 5 | 1 | ||
#12 | F | 79 | M0 | normal | 5 | 9 | ||
#13 | M | 52 | M4 | normal | 4 | CR | No | 24+ |
#14 | F | 61 | M2 | t(11;22) | 4 | CR | Yes | 11 |